TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.

Original reporting
Published Nov 5, 2026, 10:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ARQT
Bullish
high confidence
Mentioned
$ARQT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ARQTBullishMed
01

Why it matters

The earnings beat and guidance raise provide a catalyst for short-term price appreciation.

02

Market read

Earnings and guidance update are primary drivers for ARQT's near-term trade.

03

What to watch

Potential regulatory or competitive risks for Zoryve.

Relevance 8/10Novelty 8/10Timing: today

Background

Arctus Biotherapeutics reported Q3 2026 results, beating revenue expectations but missing earnings, and raised its 2026 guidance.

Company-level read

Ticker impact

$ARQTBullishHigh confidence
Context

TD Cowen raised its price target to $40 and noted Q3 revenue beat and guidance increase for Arctus Biotherapeutics.

Expected impact

likely upward pressure as investors price in higher guidance and target.

Evidence & confidence

The analyst upgrade and guidance increase are fresh, material information for a biotech with a key product.

Market effects

Positive earnings may lift other dermatology biotech peers.

US biotech sector could see modest gains.

Limited to biotech investors.

Counterpoint

Guidance may be optimistic given high spending and earnings miss.

Key entities

  • Arctus Biotherapeutics

    Biotech firm developing Zoryve for vitiligo.

  • TD Cowen

    Raised price target and maintained Buy rating.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.